Latanoprost/Timolol Zentiva (Timolol Maleate, Latanoprost)

Latanoprost increases the outflow of aqueous humor through the uveoscleral pathway, while Timolol reduces the production of aqueous humor by blocking beta‑adrenergic receptors in the ciliary body. Together they provide a complementary reduction in eye pressure.

The dosing regimen is determined by the prescribing ophthalmologist based on the patient’s condition, response, and tolerance. Typically, one drop is instilled in the affected eye(s) once daily, but the exact schedule should follow the prescriber’s instructions.

Safety in pregnancy and lactation has not been fully established. The product should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Compared with monotherapy agents, the combination offers dual mechanisms—enhanced outflow and reduced production—often achieving greater pressure reduction with a single drop. It may be preferred when single‑agent therapy does not reach target pressure, but individual response and tolerance vary.

Store the eye‑drop bottle at room temperature, away from direct sunlight and moisture. Keep it in the original packaging until use, and discard any remaining solution after the indicated period after opening, typically 30 days, as advised by the label.

The solution is applied as a single drop into the conjunctival sac of each affected eye, usually in the evening. The patient should avoid touching the tip of the bottle to the eye or any surface to maintain sterility.

Serious risks include severe allergic reactions, marked reduction in intra‑ocular pressure leading to hypotony, bronchospasm in susceptible individuals, and systemic cardiovascular effects such as bradycardia or chest pain. Patients should seek immediate medical attention if these occur.

The product is contraindicated in patients with known hypersensitivity to either component, severe bronchial asthma, chronic obstructive pulmonary disease, sinus bradycardia, second‑ or third‑degree heart block, or in those using non‑selective systemic beta‑blockers without medical supervision.